Search Results 241-250 of 23795 for prostate cancer
The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer.
Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. · More about research at Mayo Clinic.
... prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.
The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient ...
... prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer. It is given in patients with suspected metastasis (cancer that ...
Using genetic sequencing to improve prostate cancer treatment. By looking at the genetic makeup of men with prostate cancer, Mayo Clinic is helping doctors ...
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using ...
... prostate cancer. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens ...
“The prostate gland is a gland that sits around the urethra in men just below the bladder. That gland then is responsible for producing semen.” But cancer isn't ...
Learn about detection, diagnostic approaches, treatment options and advances for prostate cancer, including robotic prostatectomy and current research.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.